FK506治疗大鼠早期膜性肾病的实验研究.docVIP

FK506治疗大鼠早期膜性肾病的实验研究 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：FK506治疗大鼠早期膜性肾病的实验研究 1 1 材料与方法 3 2 结 果 4 3 讨 论 6 文2：来氟米特治疗膜性肾病的疗效观察 8 参考文摘引言： 10 原创性声明（模板） 11 文章致谢（模板） 11 正文 FK506治疗大鼠早期膜性肾病的实验研究 文1：FK506治疗大鼠早期膜性肾病的实验研究 【Abstract】 Objective To investigate the effect of FK506 on the membranous nephropathy in rat. Methods Membranous nephropathy rats were induced by CBSA. Wistar rats were divided into normal control (N),membranous nephropathy (M),and FK506 treatment (FK506) groups. Urinary protein excretion was measured at 2, 4, 6, 8 w from the beginning of immunization. The rat blood was obtained via cardiac puncture, and the kidneys were removed. The blood samples were saved for measuring the levels of serum BUN, Scr and ALB. Kidney specime were routinely processed for light microscopy. Immunohistochemistry method was performed to observe the expressio of TGFβ1 and NFκB. TGFβ protein expression was measured by Western blot. Results Urinary protein excretion in group M was significantly higher than that in group N. The level of serum ALB in group M was lower than that in group N. Upregulation of TGFβ1 and NFκB expression were observed in immunohistochemical findings. Conclusio with that in M group, urinary protein excretion was significantly decreased and the level of serum ALB was significantly increased in FK506 group. Immunohistochemistry showed that the expressio of TGFβ1 and NFκB were significantly lower in FK506 group than those in group M. The TGFβ1 protein expression was significantly lower in FK506 group than that in M group by Western blot. Conclusio FK506 can reduce urinary protein excretion, increase the level of ALB, improve kidney pathological changes, inhibit TGFβ1 overexpression and NFκB activation in renal tissue of membranous nephropathy rats, and can be used for treatment of early membranous nephropathy. 【Key words】 FK506; TGFβ1; Membranous nephropathy 膜性肾病(membranous nephropathy，MN)是中老年人常见的肾脏疾病，临床以无症状蛋白尿或肾病综合征为主要表现，